Date published: 2026-4-29

1-800-457-3801

SCBT Portrait Logo
Seach Input

PCTAIRE-3 Activators

PCTAIRE-3 Activators encompass a range of chemical compounds that, through various signaling pathways, indirectly enhance the functional activity of PCTAIRE-3. Compounds such as Forskolin and Dibutyryl-cAMP elevate intracellular cAMP, thereby activating PKA, which is known to phosphorylate target proteins, potentially including PCTAIRE-3, thereby enhancing its kinase activity in processes like cell cycle regulation. Similarly, Isoproterenol, a beta-adrenergic agonist, also raises cAMP levels, indirectly promoting PCTAIRE-3 activation. Retinoic Acid modulates cellular differentiation, which could implicate PCTAIRE-3 in the enhanced signaling required for these processes, especially in neuronal cells. Epigallocatechin Gallate (EGCG) and Staurosporine, both kinase inhibitors, could selectively inhibit kinases that normally suppress PCTAIRE-3, allowing for an indirect increase in its activity. Sphingosine-1-phosphate, while primarily involved in signal transduction, could intersect with pathways that engage PCTAIRE-3, enhancing its activity in cellular signaling.

Furthermore, compounds like LY294002, a PI3K inhibitor, and PD98059, an MEK inhibitor, may shift cellular signaling dynamics, leading to an indirect upregulation of PCTAIRE-3 activity. These inhibitors could reduce the activity of competing pathways or release PCTAIRE-3 from negative regulation. A23187 (Calcimycin) increases intracellular calcium, potentially affecting calcium-dependent protein kinases and phosphatases that modulate PCTAIRE-3's role, leading to enhanced activity. IBMX, by inhibiting phosphodiesterases, increases cAMP levels, which may further contribute to PKA-mediated activation of PCTAIRE-3. Lastly, Zoledronic Acid, by interfering with the mevalonate pathway, could alter the function or localization of proteins interacting with PCTAIRE-3, thereby enhancing its kinase activity. Collectively, these activators, through their targeted biochemical mechanisms, facilitate the enhancement of PCTAIRE-3 mediated functions in various cellular contexts.

SEE ALSO...

Items 11 to 17 of 17 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

A23187

52665-69-7sc-3591
sc-3591B
sc-3591A
sc-3591C
1 mg
5 mg
10 mg
25 mg
$55.00
$131.00
$203.00
$317.00
23
(1)

A23187 increases intracellular calcium levels, potentially affecting calcium-dependent protein kinases and phosphatases that modulate PCTAIRE-3 activity and its role in cellular functions.

Isoproterenol Hydrochloride

51-30-9sc-202188
sc-202188A
100 mg
500 mg
$28.00
$38.00
5
(0)

Isoproterenol, a beta-adrenergic agonist, elevates cAMP levels and thereby activates PKA, which may enhance PCTAIRE-3 by phosphorylation or changes in interaction with binding partners.

Cilostazol

73963-72-1sc-201182
sc-201182A
10 mg
50 mg
$109.00
$322.00
3
(1)

Cilostazol is a phosphodiesterase 3 inhibitor that elevates cAMP levels, which can enhance PKA activity. PKA, in turn, may phosphorylate and activate PCTAIRE-3.

Anagrelide

68475-42-3sc-491875
25 mg
$150.00
(0)

Anagrelide inhibits PDE3, leading to increased cAMP and PKA activation. PKA could then phosphorylate PCTAIRE-3, enhancing its activity.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

PD98059, an MEK inhibitor, could modulate MAPK/ERK pathway activity, potentially leading to altered PCTAIRE-3 activity as a result of changes in the signaling network.

Vinpocetine

42971-09-5sc-201204
sc-201204A
sc-201204B
20 mg
100 mg
15 g
$55.00
$214.00
$2400.00
4
(1)

Vinpocetine is a PDE1 inhibitor that also increases cAMP levels, potentially leading to PKA-mediated phosphorylation and activation of PCTAIRE-3.

Zoledronic acid, anhydrous

118072-93-8sc-364663
sc-364663A
25 mg
100 mg
$92.00
$256.00
5
(0)

Zoledronic acid interferes with mevalonate pathway, potentially altering prenylation and thus activity or localization of proteins that interact with PCTAIRE-3, leading to its enhanced activity.